Bilateral renal vein thrombosis in a preterm with Netherton syndrome.

Ana Roche-Gomez, Diana Voskanyan, Joanna Śladowska-Kozłowska, Giulia Bassanese, Claus Peter Schmitt

Abstract readCase Reports

In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ana Roche-GomezPediatric Nephrology Department, Hospital Universitario 12 de Octubre, Madrid, Spain. ana.rochegomez@gmail.com.ORCID 0009-0000-8472-1670

Diana VoskanyanPediatric Nephrology Department, Arabkir Joint Medical Center and Institute of Child and Adolescent Health, Yerevan, Armenia.

Joanna Śladowska-KozłowskaUniversity of Heidelberg, Medical Faculty Heidelberg, Center for Pediatric and Adolescent Medicine, Clinic 1, Pediatric Nephrology, Heidelberg, Germany.

Giulia BassaneseUniversity of Heidelberg, Medical Faculty Heidelberg, Center for Pediatric and Adolescent Medicine, Clinic 1, Pediatric Nephrology, Heidelberg, Germany.

Claus Peter SchmittUniversity of Heidelberg, Medical Faculty Heidelberg, Center for Pediatric and Adolescent Medicine, Clinic 1, Pediatric Nephrology, Heidelberg, Germany. ClausPeter.Schmitt@med.uni-heidelberg.de.

Funding

Projekt DEAL

6 · The paper itself

Abstract

Netherton syndrome (NS) is a rare autosomal recessive syndrome caused by mutations in the serine protease inhibitor of the Kazal type 5 (SPINK5) gene. Patients are characterized by the classic triad of congenital ichthyosiform erythroderma, a hair shaft abnormality termed trichorrhexis invaginata and atopic diathesis. These children require meticulous fluid and salt control from the first day of life to prevent kidney damage due to the defective skin barrier.

Indexed as

Netherton SyndromeRenal VeinsVenous ThrombosisHumansInfant, NewbornInfant, PrematureSerine Peptidase Inhibitor Kazal-Type 5Serine Peptidase Inhibitor Kazal-Type 5SPINK5 protein, humanAcute kidney injuryHypernatremiaKidney vein thrombosisNetherton syndrome

Identifiers

PMID40471236

DOI10.1007/s00467-025-06821-2

PMCPMC12484293

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.